Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Other Routine +

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Strategic Execution of Global Ziftomenib Pipeline Following US Approval

By The Northwire Desk — AI Analysis Apr 24, 2026 · 08:00 4151
Executive Summary
  • The most recent release (April 24, 2026) announces the initiation of a Japanese Phase 2 Registration-Directed Trial for ziftomenib (KOMZIFTI™) in relapsed/refractory NPM1-mutated AML.
  • This trial is part of Kyowa Kirin's global license agreement with Kura Oncology, where Kyowa leads development outside the U.S. and intends to file for regulatory approval in Japan upon completion.
  • The drug received FDA full approval in November 2025 (U.S.) based on the KOMET-001 trial showing a 21.4% CR+CRh rate.
  • Previous news (December 2025) showed robust combination data for ziftomenib with venetoclax and azacitidine, supporting expanded use in newly diagnosed AML.
  • Earlier news (January 2026) highlighted Kyowa Kirin regaining full control of the Rocatinlimab program from Amgen after Phase 3 success, with U.S. filing planned for H1 2026.
  • The pipeline also includes OTL-200 receiving Orphan Regenerative Medicine Product Designation in Japan (October 2025) for metachromatic leukodystrophy.
Material Impact
  • Rating Justification: The news is categorized as Routine - Positive because the initiation of a registration trial in Japan was anticipated under the November 2024 global license agreement where Kyowa Kirin leads non-U.S. development.
  • Progression Validation: The timeline confirms execution following U.S. approval (November 2025) and combination data release (December 2025), indicating no significant delays in the global rollout strategy.
  • Revenue Implications: While positive, this does not represent a sudden valuation shift but rather the de-risking of international revenue streams for an already approved asset.
  • Strategic Consistency: The move aligns with previous announcements regarding Rocatinlimab (regaining control) and OTL-200 (rare disease expansion), showing consistent pipeline management without major pivots or setbacks.
  • Risk Mitigation: Proceeding with registration trials immediately after U.S. approval reduces the risk of regulatory divergence between markets, though it does not eliminate execution risk in Japan.
4151 · Price
Company Overview
  • Company Profile: Kyowa Kirin is a pharmaceutical company with a focus on hematologic malignancies, rare diseases, and inflammatory conditions.
  • Flagship Project 1: Ziftomenib (KOMZIFTI™): An oral menin inhibitor for NPM1-mutated AML. FDA approved in November 2025; currently advancing registration trials in Japan. Partnership with Kura Oncology splits U.S. and non-U.S. rights.
  • Flagship Project 2: Rocatinlimab: An OX40-targeted therapy for atopic dermatitis. Phase 3 data met endpoints; Kyowa Kirin regained full control from Amgen in January 2026 with U.S. filing planned for H1 2026.
  • Flagship Project 3: OTL-200: Gene therapy for metachromatic leukodystrophy (MLD). Received Orphan Regenerative Medicine Product Designation in Japan in October 2025.
Read the original news release →

More from

Jun 30, 2026 · 08:30

Rare disease and oncology specialist advancing lifecycle management for POTELIGEO, CRYSVITA, and KOMZIFTI while transitioning key dermatology assets in-house.

Other Jun 29, 2026 · 08:30

Rare disease and oncology franchise delivering consistent, incremental clinical and regulatory milestones across multiple asset portfolios.

Other Jun 23, 2026 · 08:30

Rare disease and oncology portfolio advancing with regulatory wins, expanded access, and strategic pipeline consolidation.

M&A / Property Jun 10, 2026 · 08:00

Pipeline-driven biopharma advancing rare disease and oncology franchises with incremental clinical evidence and regulatory wins.

Other May 14, 2026 · 08:30

Kyowa Kirin Expands CRYSVITA Dosing Flexibility Amidst Pipeline Momentum

Regulatory May 06, 2026 · 08:00

Kyowa Kirin Expands CRYSVITA Access, But Oncology Pipeline Risks Loom

Other